Drug MNCs Leap At Chance To Buy Brazil's Ache For Up To $4 Billion
This article was originally published in PharmAsia News
Executive Summary
Multinational drug makers such as Abbott Laboratories, GlaxoSmithKline, Novartis and Pfizer appear to be lining up to buy Ache Laboratories Farmaceuticos, one of Brazil's largest drug makers, which may be seeking to sell for up to $4 billion.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.